Why Kolabtree
Getting started is quick and easy. No upfront fees
It’s free to request a service and invite bids from experts
Discuss requirements with the expert in detail before accepting statement of work from Kolabtree
Collaborate with the expert directly to get your work done the right way
Fund project when you hire the expert, but approve the deliverables only once work is done
Want to hire this expert for a project? Request a quote for free.
Profile Details
Create Project
USD 70 /hr
Hire Dr. Keith L.
United States
USD 70 /hr

Experienced investigator of the responses of mammalian cells to diverse stresses including cytotoxic/cytostatic agents

Profile Summary
Subject Matter Expertise
Writing Technical Writing
Research Fact Checking, Gray Literature Search, Systematic Literature Review, Secondary Data Collection
Work Experience

Senior Research Scientist

SRI International

2008 - 2020

Director, Cancer Biology Program

SRI International

1994 - 2008

Cancer Biologist

SRI International

1989 - 1994

Research Associate

National Research Council Canada

1987 - 1989


Postdoctoral Fellow (Physics Division)

Ontario Cancer Institute

1984 - 1987

PhD (Organic Chemistry)

University of Toronto

- 1985

  • Certification details not provided.
(2016). Abstract B36: Developing circRNA signatures as a biomarker for the early diagnosis of pancreatic carcinoma. AACR Special Conference on Noncoding RNAs and Cancer: Mechanisms to Medicines.
(2009). Selective deficiency of HIF-1alpha in myeloid cells influences secondary intention wound healing in mouse skin. In vivo (Athens, Greece).
(2008). Changes to NIH grant system may backfire . Science (New York, N.Y.).
(2004). Pathway logic modeling of protein functional domains in signal transduction. Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing.
(2002). Pathway logic: symbolic analysis of biological signaling. Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing.
(2001). The novel tubulin-binding drug BTO-956 inhibits R3230AC mammary carcinoma growth and angiogenesis in Fischer 344 rats. Clinical cancer research : an official journal of the American Association for Cancer Research.
(2001). c-jun cooperates with SV40 T-antigen to sustain MMP-2 expression in immortalized cells . Biochemical and biophysical research communications.
(2001). Placenta growth factor gene expression is induced by hypoxia in fibroblasts: a central role for metal transcription factor-1. Cancer research.
(2000). Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor. Clinical cancer research : an official journal of the American Association for Cancer Research.
(2000). Epigenetic regulation of gene expression in cervical cancer cells by the tumor microenvironment. Clinical cancer research : an official journal of the American Association for Cancer Research.
(1999). Activation of metallothionein gene expression by hypoxia involves metal response elements and metal transcription factor-1. Cancer research.
(1998). Inhibition of human bladder cancer cell motility by genistein is dependent on epidermal growth factor receptor but not p21ras gene expression. International journal of cancer.
(1998). Epidermal growth factor receptor-regulated human bladder cancer motility is in part a phosphatidylinositol 3-kinase-mediated process. Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
(1997). Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood.
(1997). Protease inhibitor TPCK represses Ha-ras (Val12) transformation and nuclear factor-kappa B activation. International journal of oncology.
(1996). Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer research.
(1996). Expression of the ATDC (ataxia telangiectasia group D-complementing) gene in A431 human squamous carcinoma cells. International journal of cancer.
(1996). Early responses of SiHa human squamous carcinoma cells to hypoxic signals. International Journal of Oncology.
(1995). Mapping of the vascular endothelial growth factor-producing hypoxic cells in multicellular tumor spheroids using a hypoxia-specific marker. Cancer research.
(1994). Metallothionein IIA is up-regulated by hypoxia in human A431 squamous carcinoma cells. Cancer research.
(1994). Synergistic interaction between tirapazamine and cyclophosphamide in human breast cancer xenografts. Cancer research.
(1994). Epidermal growth factor modifies cell cycle control in A431 human squamous carcinoma cells damaged by ionizing radiation. Cancer research.
(1993). Enhancement of heme oxygenase expression and activity in A431 squamous carcinoma multicellular tumor spheroids. Cancer research.
(1989). NLP-1: a DNA intercalating hypoxic cell radiosensitizer and cytotoxin . International journal of radiation oncology, biology, physics.
(1985). K. R. Laderoute and A. G. Harrison. Concerning the equilibration of oxygen atoms in the molecular ions of methyl esters. Org. Mass Spectrom. 20, 374-376, 1985.
(1985). K. R. Laderoute and A. G. Harrison. Cyclopropane intermediates in the rearrangement and fragmentation of olefinic molecular ions. Org. Mass Spectrom. 20, 624-630, 1985.
(1985). K. R. Laderoute, J. J. Zwinselman, and A. G. Harrison. Characterization of five [C4H7O]+ Ion Structures. Fragmentation of the 2-pentanone molecular ion. Org. Mass Spectrom. 20, 25-33, 1985.
(1980). J. W. Bunting, K. R. Laderoute, and D. J. Norris. The pH dependence of xanthine oxidase catalysis in basic solution. Can. J. Biochem. 58, 394-398, 1980.
(1980). J. W. Bunting, K. R. Laderoute, and D. J. Norris. Specificity of xanthine oxidase for nitrogen heteroaromatic cation substrates. Can. J. Biochem. 58, 49-57, 1980.
(2007). A. Tiwari, C. Talcott, M. Knapp, P. Lincoln, and K. Laderoute. Analyzing biological pathways using SAT-based approaches.
(2007). B. Parvin, N. Ghosh, L. Heiser, M. Knapp, C. Talcott, K. Laderoute, J. Gray, and P. Spellman. Spectral decomposition of signaling networks. Proceedings of the IEEE Symposium on Computational Intelligence in Bioinformatics and Computational Biology, April 1-5, 2007, Honolulu, HI.
(2003). S. Eker, K. Laderoute, P. Lincoln, M. G. Sriram, C. Talcott. Representing and simulating protein functional domains in signal transduction using MAUDE. International Workshop on Computational Methods in Systems Biology. February 24-26, 2003, Roverto Italy. Springer-Verlag.
(2002). Steven Eker, Merrill Knapp, Patrick Lincoln, Keith Laderoute, Carolyn Talcott. Pathway Logic: Executable models of biological networks. 4th International Workshop on Rewriting Logic and its Applications (WRLA’2002). September 19-21, 2002, Pisa, Italy. Springer-Verlag.
(1991). R. M. Sutherland, W. A. Ausserer, T. D. Grant, A. M. Knapp, T. T. Kwok, K. R. Laderoute, S. C. Miller, and J. N. Mansbridge. Regulatory polypeptide growth factors, signal transduction, and radiation response. Ninth International Conference on Radiation Research, 1991, Toronto, Ontario: Academic Press.
(2002). D. Tuse', C. Hiebert, K. R. Laderoute, and N. Waleh. Method for inhibiting inflammatory disease.
(2001). K. A. Webster, N. H. Bishopric, B. Murphy, K. R. Laderoute, and C. J. Green. Tissue specific hypoxia regulated constructs.
(2001). D. Tuse', X. Chen, C. K. Hiebert, C. M. Olsen, K. Laderoute, N. Waleh, and A. M. Knapp. Di-aryl ethers and their derivatives as anti-cancer agents.
(2000). D. Tuse', C. Hiebert, K. R. Laderoute, and N. Waleh. Methods for inhibiting angiogenesis.